Yokoyama S - Search Results

1

Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.

Kawamoto K, Miyoshi H, Suzuki T, Kiyasu J, Yokoyama S, Sasaki Y, Sone H, Seto M, Takizawa J, Ohshima K. Kawamoto K, et al. Among authors: yokoyama s. Hematol Oncol. 2018 Aug;36(3):591-599. doi: 10.1002/hon.2506. Epub 2018 Mar 30. Hematol Oncol. 2018. PMID: 29602174

2

Thymoma in Patient with Myasthenia Gravis Has Significantly Fewer Forkhead Box P3 Positive Lymphocytes than that without One.

Nishi T, Yokoyama S, Takamori S, Matsuo T, Murakami D, Akagi Y, Ohshima K. Nishi T, et al. Among authors: yokoyama s. Kurume Med J. 2015;61(3-4):65-71. doi: 10.2739/kurumemedj.MS65002. Epub 2015 Aug 25. Kurume Med J. 2015. PMID: 26460311 Free article.

3

Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma.

Yokoyama S, Miyoshi H, Nishi T, Hashiguchi T, Mitsuoka M, Takamori S, Akagi Y, Kakuma T, Ohshima K. Yokoyama S, et al. Ann Thorac Surg. 2016 Apr;101(4):1361-9. doi: 10.1016/j.athoracsur.2015.10.044. Epub 2016 Jan 12. Ann Thorac Surg. 2016. PMID: 26794891

4

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.

Yokoyama S, Miyoshi H, Nakashima K, Shimono J, Hashiguchi T, Mitsuoka M, Takamori S, Akagi Y, Ohshima K. Yokoyama S, et al. Clin Cancer Res. 2016 Sep 15;22(18):4727-34. doi: 10.1158/1078-0432.CCR-16-0434. Epub 2016 May 10. Clin Cancer Res. 2016. PMID: 27166394

5

GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas.

Haraguchi T, Miyoshi H, Hiraoka K, Yokoyama S, Ishibashi Y, Hashiguchi T, Matsuda K, Hamada T, Okawa T, Shiba N, Ohshima K. Haraguchi T, et al. Among authors: yokoyama s. PLoS One. 2016 Jun 1;11(6):e0156524. doi: 10.1371/journal.pone.0156524. eCollection 2016. PLoS One. 2016. PMID: 27249072 Free PMC article.

6

PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.

Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, Taniguchi H, Sasaki Y, Kurita D, Kawamoto K, Kato K, Imaizumi Y, Seto M, Ohshima K. Miyoshi H, et al. Among authors: yokoyama s. Blood. 2016 Sep 8;128(10):1374-81. doi: 10.1182/blood-2016-02-698936. Epub 2016 Jul 14. Blood. 2016. PMID: 27418641 Free article.

7

Prognostic impact of GATA binding protein-3 expression in primary lung adenocarcinoma.

Hashiguchi T, Miyoshi H, Nakashima K, Yokoyama S, Matsumoto R, Murakami D, Mitsuoka M, Takamori S, Akagi Y, Ohshima K. Hashiguchi T, et al. Among authors: yokoyama s. Hum Pathol. 2017 May;63:157-164. doi: 10.1016/j.humpath.2017.02.024. Epub 2017 Mar 16. Hum Pathol. 2017. PMID: 28322854

8

Papillary thyroid carcinoma expressing CD20.

Sasaki Y, Seto M, Miyoshi H, Okada S, Yokoyama S, Ohshima A, Ohshima K. Sasaki Y, et al. Among authors: yokoyama s. Pathol Int. 2017 Jul;67(7):350-354. doi: 10.1111/pin.12548. Epub 2017 Jun 15. Pathol Int. 2017. PMID: 28618063

9

Clinicopathological and prognostic value of transforming acidic coiled-coil-containing protein 3 (TACC3) expression in soft tissue sarcomas.

Matsuda K, Miyoshi H, Hiraoka K, Yokoyama S, Haraguchi T, Hashiguchi T, Hamada T, Shiba N, Ohshima K. Matsuda K, et al. Among authors: yokoyama s. PLoS One. 2017 Nov 14;12(11):e0188096. doi: 10.1371/journal.pone.0188096. eCollection 2017. PLoS One. 2017. PMID: 29135996 Free PMC article.

10

Thymic tumors and immune checkpoint inhibitors.

Yokoyama S, Miyoshi H. Yokoyama S, et al. J Thorac Dis. 2018 May;10(Suppl 13):S1509-S1515. doi: 10.21037/jtd.2017.10.157. J Thorac Dis. 2018. PMID: 29951302 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,593 results

Search Page

Filters